ClinicalTrials.gg
CompletedNCT03268811Updated May 24, 2022Results posted

A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302

A Phase 3 interventional study of Teduglutide in Short Bowel Syndrome, sponsored by Shire. Completed at 6 sites in Japan. Per ClinicalTrials.gov, last updated 2022-05-24.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
17th of 20
9 · median 20
Started
2017
with 1 other
Phase 3
16 of 20
none open now
Registered
13th of 20
by date
Lead sponsor
13 of 20
Shire

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 17th largest by enrollment, is one of 2 that started in 2017, is one of 16 in phase 3, and was the 13th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The purpose of this clinical study is to evaluate the long-term safety and tolerability of teduglutide treatment in Japanese pediatric participants with short bowel syndrome (SBS) who completed Study SHP633-302 (NCT02980666).

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • by a parent or guardian prior to any study-related procedures.
  • When applicable, informed assent (as deemed appropriate by the Institutional Review Board [IRB]) by the participant prior to any study-related procedures.
  • Participant completed Study SHP633-302 (NCT02980666).
  • Participant (and/or parent/guardian) understands and is willing and able to fully adhere to study requirements as defined in this protocol.

Exclusion criteria

Exclusion Criteria:

There are no exclusion criteria for this study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Teduglutide

    Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24-week intervals. If a participant deteriorates during a follow-up period, the participant may be evaluated immediately for additional teduglutide treatment (24-week interval) until teduglutide is commercially available for each participant, the participant's participation in this study is discontinued, or the study is discontinued.

    Drug: Teduglutide

Interventions

  • Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An Adverse Event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened or intensity increased after receiving the investigational product (IP) in the core study (SHP633-302 \[NCT02980666\]) or this extension study. Number of participants with TEAEs were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: From Baseline up to follow-up (up to 50 months)

  2. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Vital sign assessments included pulse rate, blood pressure (systolic and diastolic blood pressure) and body temperature. Number of participants with clinically significant abnormalities in vital signs which were deemed clinically significant by the investigator were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: From Baseline up to follow-up (up to 50 months)

  3. Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

    Clinical laboratory parameters included biochemistry, hematology and urinalysis. Number of participants with clinically significant abnormalities in laboratory parameters which were deemed clinically significant by the investigator were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: From Baseline up to follow-up (up to 50 months)

  4. Percent Change From Baseline in Average Total Urine Output at End of Treatment (EOT) of Last Cycle During Teduglutide Treatment

    Average total urine output was recorded over a 48-hour period of parental support (PS) stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The Average daily urine output milliliter per kilogram per day (mL/kg/day) was calculated as: (Total urine output over 48 hours / 2) / body weight (kilogram \[kg\]) where total urine output was calculated as the sum of the urine output in milliliter (mL) and the urine-only diaper weights in gram (g) (1g = 1mL) for the participant collected on the output diary form of electronic case report from (eCRF). Percent change from baseline in average total urine output at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  5. Percent Change From Baseline in Average Number of Stools Per Day at EOT of Last Cycle During Teduglutide Treatment

    Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized by the average number of stools per day. The average number of stools per day was calculated as (sum of the daily data in a 48-hour period/2). Percent change from baseline in average number of stools per day at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  6. Percent Change From Baseline in Average Stool/Mixed Stool Diaper Weight at EOT of Last Cycle During Teduglutide Treatment

    Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized by the average stool/mixed stool diaper weight (gram per kilogram per day \[g/kg/day\]). The body weight was used to calculate the daily stool/mixed stool diaper weight (g/kg/day). Percent change from baseline in average stool/mixed stool diaper weight at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  7. Percent Change From Baseline in Average Total Ostomy Output at EOT of Last Cycle During Teduglutide Treatment

    Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The body weight was used to calculate the average total ostomy output per day (mL/kg/day) using a formula analogous to that used to calculate the average daily urine output. Percent change from baseline in average total ostomy output at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  8. Percent Change From Baseline in Average Bristol Stool Form Score at EOT of Last Cycle During Teduglutide Treatment

    Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized the average typical stool form score using Bristol Stool Form Scale. The average typical stool form score was calculated as (sum of the daily data in a 48-hour period / 2). Typical Stool Form based on Bristol Stool Form Scale: 1 - Separate hard lumps, hard to pass, 2 - Sausage-shaped, but lumpy, 3 - Like a sausage but with cracks on the surface, 4- Like a sausage or snake, smooth and soft, 5- Soft blobs with clear-cut edges, 6- Fluffy pieces with ragged edges, a mushy stool, 7- Watery, no solid pieces. Entirely liquid. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]). A negative change from baseline indicates improvement.

    Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  9. Number of Participants With Anti-drug Antibodies (ADAs) (Including Neutralizing Antibodies) at EOT of Last Cycle During Teduglutide Treatment

    Number of participants with ADAs (including NAbs) to teduglutide were used to summarize the presence of antibodies. The participants who tested positive only for ADAs (including NAbs) were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  10. Number of Participants With Clinically Significant Changes in Gastrointestinal (GI) Specific Testing

    GI specific testing included colonoscopy or sigmoidoscopy, abdominal ultrasound, fecal occult blood testing, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with clinically significant changes findings in gastrointestinal specific testing were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  11. Change From Baseline in Body Weight For Age Z-Score at EOT of Last Cycle During Teduglutide Treatment

    Body weight was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-Score at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  12. Change From Baseline in Height For Age Z-Score at EOT of Cycle 1 During Teduglutide Treatment

    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-Score at EOT of cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 1 (up to 24 Weeks)

  13. Change From Baseline in Height For Age Z-Score at EOT of Cycle 2 During Teduglutide Treatment

    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 2 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 2 (up to 48 weeks)

  14. Change From Baseline in Height For Age Z-Score at EOT of Cycle 3 During Teduglutide Treatment

    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 3 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 3 (up to 72 weeks)

  15. Change From Baseline in Height For Age Z-Score at EOT of Cycle 4 During Teduglutide Treatment

    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 4 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 4 (up to 96 weeks)

  16. Change From Baseline in Height For Age Z-Score at EOT of Cycle 5 During Teduglutide Treatment

    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 5 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 5 (up to 120 weeks)

  17. Change From Baseline in Height For Age Z-Score at EOT of Cycle 6 During Teduglutide Treatment

    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 6 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 6 (up to 144 weeks)

  18. Change From Baseline in Height For Age Z-Score at EOT of Cycle 7 During Teduglutide Treatment

    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 7 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 7 (up to 168 weeks)

  19. Change From Baseline in Height For Age Z-Score at EOT of Cycle 8 During Teduglutide Treatment

    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 8 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 8 (up to 192 weeks)

  20. Change From Baseline in Height For Age Z-Score at EOT of Cycle 9 During Teduglutide Treatment

    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 9 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 9 (up to 196 weeks)

  21. Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment

    Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 1 (up to 24 weeks)

  22. Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment

    Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 2 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 2 (up to 48 weeks)

  23. Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment

    Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 3 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 3 (up to 72 weeks)

  24. Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment

    Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 4 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 4 (up to 76 weeks)

  25. Change From Baseline in Body Mass Index (BMI) for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment

    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 1 (up to 24 weeks)

  26. Change From Baseline in BMI for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment

    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 2 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 2 (up to 48 weeks)

  27. Change From Baseline in BMI for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment

    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 3 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 3 (up to 72 weeks)

  28. Change From Baseline in BMI for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment

    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 4 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 4 (up to 96 weeks)

  29. Change From Baseline in BMI for Age Z-score at EOT of Cycle 5 During Teduglutide Treatment

    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 5 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 5 (up to 120 weeks)

  30. Change From Baseline in BMI for Age Z-score at EOT of Cycle 6 During Teduglutide Treatment

    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 6 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 6 (up to 144 weeks)

  31. Change From Baseline in BMI for Age Z-score at EOT of Cycle 7 During Teduglutide Treatment

    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 7 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 7 (up to 168 weeks)

  32. Change From Baseline in BMI for Age Z-score at EOT of Cycle 8 During Teduglutide Treatment

    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 8 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 8 (up to 192 weeks)

  33. Change From Baseline in BMI for Age Z-score at EOT of Cycle 9 During Teduglutide Treatment

    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 9 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of Cycle 9 (up to 196 weeks)

Secondary outcomes

  1. Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Participants Diary Parenteral Support (PS) Volume at EOT of Each Cycle During Teduglutide Treatment

    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent reduction in weight-normalized diary PS values from baseline was calculated using the formula: % reduction in PS value at the visit = (\[average daily value at the scheduled visit - average daily value at baseline of the core study (SHP633-302 \[NCT02980666\]) / average daily value at baseline of the core study (SHP633-302 \[NCT02980666\])) \*100. Number of participants who achieved at least 20% reduction from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  2. Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment

    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent reduction in weight-normalized prescribed PS values from baseline was calculated using the formula: % reduction in PS value at the visit =(\[average daily value at the scheduled visit - average daily value at baseline of the core study (SHP633-302 \[NCT02980666\]) / average daily value at baseline of the core study (SHP633-302 \[NCT02980666\])) \*100. Number of participants who achieved at least 20% reduction from baseline in Investigator prescribed PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  3. Change From Baseline in Participant Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment

    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Change from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  4. Percent Change From Baseline in Participant Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment

    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent change from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  5. Change From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment

    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Change from baseline in investigator prescribed PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  6. Percent Change From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment

    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent change from baseline in investigator prescribed PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  7. Number of Participants Who Achieved Enteral Autonomy PS Volume at EOT of Each Cycle During Teduglutide Treatment

    Enteral autonomy (completely weaned off PS) was defined as the first visit where there is no use of PS for the 7 days prior to the visit and there is no prescribed PS at that visit, and the participants remains off PS for the remainder of the treatment period of that cycle. Number of participants who achieved enteral autonomy off PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  8. Change From Baseline in Days Per Week of Diary PS Usage at EOT of Each Cycle During Teduglutide Treatment

    Days per week of diary PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) \* 7. Change from baseline in days per week of diary PS usage at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

  9. Change From Baseline in Days Per Week of Prescribed PS Usage at EOT of Each Cycle During Teduglutide Treatment

    Change from baseline in days per week of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported. Days per week of diary PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) \* 7. Change from baseline in days Per week of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

    Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)

07

Results

Posted May 24, 2022

Participant flow

The study was conducted at 6 centers in Japan from 23 August 2017 (first participant first visit) and 02 November 2021 (last participant last visit).

Participant flow — Overall Study
MilestoneTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Started72
Completed71
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An Adverse Event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened or intensity increased after receiving the investigational product (IP) in the core study (SHP633-302 \[NCT02980666\]) or this extension study. Number of participants with TEAEs were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
From Baseline up to follow-up (up to 50 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)72
PrimaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs

Vital sign assessments included pulse rate, blood pressure (systolic and diastolic blood pressure) and body temperature. Number of participants with clinically significant abnormalities in vital signs which were deemed clinically significant by the investigator were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
From Baseline up to follow-up (up to 50 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants With Clinically Significant Abnormalities in Vital Signs00
PrimaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Parameters

Clinical laboratory parameters included biochemistry, hematology and urinalysis. Number of participants with clinically significant abnormalities in laboratory parameters which were deemed clinically significant by the investigator were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
From Baseline up to follow-up (up to 50 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Biochemistry51
Hematology10
Urinalysis.00
PrimaryPercent Change From Baseline in Average Total Urine Output at End of Treatment (EOT) of Last Cycle During Teduglutide Treatment

Average total urine output was recorded over a 48-hour period of parental support (PS) stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The Average daily urine output milliliter per kilogram per day (mL/kg/day) was calculated as: (Total urine output over 48 hours / 2) / body weight (kilogram \[kg\]) where total urine output was calculated as the sum of the urine output in milliliter (mL) and the urine-only diaper weights in gram (g) (1g = 1mL) for the participant collected on the output diary form of electronic case report from (eCRF). Percent change from baseline in average total urine output at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Mean · Percent change
Percent Change From Baseline in Average Total Urine Output at End of Treatment (EOT) of Last Cycle During Teduglutide Treatment
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From Baseline in Average Total Urine Output at End of Treatment (EOT) of Last Cycle During Teduglutide Treatment-37.228 ± 42.9396146.881 ± 295.8061
PrimaryPercent Change From Baseline in Average Number of Stools Per Day at EOT of Last Cycle During Teduglutide Treatment

Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized by the average number of stools per day. The average number of stools per day was calculated as (sum of the daily data in a 48-hour period/2). Percent change from baseline in average number of stools per day at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Mean · Percent change
Percent Change From Baseline in Average Number of Stools Per Day at EOT of Last Cycle During Teduglutide Treatment
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From Baseline in Average Number of Stools Per Day at EOT of Last Cycle During Teduglutide Treatment24.37 ± 63.62350.00 ± 0.000
PrimaryPercent Change From Baseline in Average Stool/Mixed Stool Diaper Weight at EOT of Last Cycle During Teduglutide Treatment

Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized by the average stool/mixed stool diaper weight (gram per kilogram per day \[g/kg/day\]). The body weight was used to calculate the daily stool/mixed stool diaper weight (g/kg/day). Percent change from baseline in average stool/mixed stool diaper weight at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Mean · Percent change
Percent Change From Baseline in Average Stool/Mixed Stool Diaper Weight at EOT of Last Cycle During Teduglutide Treatment
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From Baseline in Average Stool/Mixed Stool Diaper Weight at EOT of Last Cycle During Teduglutide Treatment-12.678 ± NA206.017 ± 332.4580
PrimaryPercent Change From Baseline in Average Total Ostomy Output at EOT of Last Cycle During Teduglutide Treatment

Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The body weight was used to calculate the average total ostomy output per day (mL/kg/day) using a formula analogous to that used to calculate the average daily urine output. Percent change from baseline in average total ostomy output at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Mean · Percent change
Percent Change From Baseline in Average Total Ostomy Output at EOT of Last Cycle During Teduglutide Treatment
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From Baseline in Average Total Ostomy Output at EOT of Last Cycle During Teduglutide Treatment—3.143 ± 145.8659
PrimaryPercent Change From Baseline in Average Bristol Stool Form Score at EOT of Last Cycle During Teduglutide Treatment

Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized the average typical stool form score using Bristol Stool Form Scale. The average typical stool form score was calculated as (sum of the daily data in a 48-hour period / 2). Typical Stool Form based on Bristol Stool Form Scale: 1 - Separate hard lumps, hard to pass, 2 - Sausage-shaped, but lumpy, 3 - Like a sausage but with cracks on the surface, 4- Like a sausage or snake, smooth and soft, 5- Soft blobs with clear-cut edges, 6- Fluffy pieces with ragged edges, a mushy stool, 7- Watery, no solid pieces. Entirely liquid. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]). A negative change from baseline indicates improvement.

Time frame:
Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Mean · Percent change
Percent Change From Baseline in Average Bristol Stool Form Score at EOT of Last Cycle During Teduglutide Treatment
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From Baseline in Average Bristol Stool Form Score at EOT of Last Cycle During Teduglutide Treatment-7.51 ± 16.7580.00 ± 0.000
PrimaryNumber of Participants With Anti-drug Antibodies (ADAs) (Including Neutralizing Antibodies) at EOT of Last Cycle During Teduglutide Treatment

Number of participants with ADAs (including NAbs) to teduglutide were used to summarize the presence of antibodies. The participants who tested positive only for ADAs (including NAbs) were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs) (Including Neutralizing Antibodies) at EOT of Last Cycle During Teduglutide Treatment
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Positive ADA at EOT of the Last Cycle50
Positive NAbs at EOT of the Last Cycle4—
PrimaryNumber of Participants With Clinically Significant Changes in Gastrointestinal (GI) Specific Testing

GI specific testing included colonoscopy or sigmoidoscopy, abdominal ultrasound, fecal occult blood testing, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with clinically significant changes findings in gastrointestinal specific testing were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Gastrointestinal (GI) Specific Testing
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants With Clinically Significant Changes in Gastrointestinal (GI) Specific Testing00
PrimaryChange From Baseline in Body Weight For Age Z-Score at EOT of Last Cycle During Teduglutide Treatment

Body weight was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-Score at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Body Weight For Age Z-Score at EOT of Last Cycle During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Body Weight For Age Z-Score at EOT of Last Cycle During Teduglutide Treatment0.229 ± 0.56363.982 ± 3.6363
PrimaryChange From Baseline in Height For Age Z-Score at EOT of Cycle 1 During Teduglutide Treatment

Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-Score at EOT of cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 1 (up to 24 Weeks)
Reported as:
Mean · Z-score
Change From Baseline in Height For Age Z-Score at EOT of Cycle 1 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 1 During Teduglutide Treatment0.002 ± 0.60491.376 ± 0.3363
PrimaryChange From Baseline in Height For Age Z-Score at EOT of Cycle 2 During Teduglutide Treatment

Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 2 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 2 (up to 48 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Height For Age Z-Score at EOT of Cycle 2 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 2 During Teduglutide Treatment0.152 ± 0.51813.114 ± NA
PrimaryChange From Baseline in Height For Age Z-Score at EOT of Cycle 3 During Teduglutide Treatment

Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 3 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 3 (up to 72 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Height For Age Z-Score at EOT of Cycle 3 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 3 During Teduglutide Treatment0.098 ± 0.34673.554 ± NA
PrimaryChange From Baseline in Height For Age Z-Score at EOT of Cycle 4 During Teduglutide Treatment

Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 4 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 4 (up to 96 weeks)
Reported as:
Mean · Z-Score
Change From Baseline in Height For Age Z-Score at EOT of Cycle 4 During Teduglutide Treatment
Z-ScoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 4 During Teduglutide Treatment0.126 ± 0.26223.542 ± NA
PrimaryChange From Baseline in Height For Age Z-Score at EOT of Cycle 5 During Teduglutide Treatment

Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 5 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 5 (up to 120 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Height For Age Z-Score at EOT of Cycle 5 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 5 During Teduglutide Treatment0.342 ± 0.1012—
PrimaryChange From Baseline in Height For Age Z-Score at EOT of Cycle 6 During Teduglutide Treatment

Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 6 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 6 (up to 144 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Height For Age Z-Score at EOT of Cycle 6 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 6 During Teduglutide Treatment0.276 ± 0.2593—
PrimaryChange From Baseline in Height For Age Z-Score at EOT of Cycle 7 During Teduglutide Treatment

Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 7 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 7 (up to 168 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Height For Age Z-Score at EOT of Cycle 7 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 7 During Teduglutide Treatment0.570 ± NA—
PrimaryChange From Baseline in Height For Age Z-Score at EOT of Cycle 8 During Teduglutide Treatment

Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 8 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 8 (up to 192 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Height For Age Z-Score at EOT of Cycle 8 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 8 During Teduglutide Treatment0.851 ± NA—
PrimaryChange From Baseline in Height For Age Z-Score at EOT of Cycle 9 During Teduglutide Treatment

Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 9 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 9 (up to 196 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Height For Age Z-Score at EOT of Cycle 9 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 9 During Teduglutide Treatment0.477 ± NA—
PrimaryChange From Baseline in Head Circumference for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment

Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 1 (up to 24 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment—2.400 ± 0.6472
PrimaryChange From Baseline in Head Circumference for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment

Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 2 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 2 (up to 48 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment—1.431 ± NA
PrimaryChange From Baseline in Head Circumference for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment

Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 3 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 3 (up to 72 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment—2.080 ± NA
PrimaryChange From Baseline in Head Circumference for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment

Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 4 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 4 (up to 76 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment—2.055 ± NA
PrimaryChange From Baseline in Body Mass Index (BMI) for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment

BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 1 (up to 24 weeks)
Reported as:
Mean · Z-score
Change From Baseline in Body Mass Index (BMI) for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Body Mass Index (BMI) for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment0.090 ± 0.6642—
PrimaryChange From Baseline in BMI for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment

BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 2 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 2 (up to 48 weeks)
Reported as:
Mean · Z-score
Change From Baseline in BMI for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment0.489 ± 0.8474—
PrimaryChange From Baseline in BMI for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment

BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 3 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 3 (up to 72 weeks)
Reported as:
Mean · Z-score
Change From Baseline in BMI for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment0.409 ± 1.1688—
PrimaryChange From Baseline in BMI for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment

BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 4 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 4 (up to 96 weeks)
Reported as:
Mean · Z-score
Change From Baseline in BMI for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment0.118 ± 0.8827—
PrimaryChange From Baseline in BMI for Age Z-score at EOT of Cycle 5 During Teduglutide Treatment

BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 5 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 5 (up to 120 weeks)
Reported as:
Mean · Z-score
Change From Baseline in BMI for Age Z-score at EOT of Cycle 5 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 5 During Teduglutide Treatment0.070 ± 0.9770—
PrimaryChange From Baseline in BMI for Age Z-score at EOT of Cycle 6 During Teduglutide Treatment

BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 6 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 6 (up to 144 weeks)
Reported as:
Mean · Z-score
Change From Baseline in BMI for Age Z-score at EOT of Cycle 6 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 6 During Teduglutide Treatment0.925 ± 0.2556—
PrimaryChange From Baseline in BMI for Age Z-score at EOT of Cycle 7 During Teduglutide Treatment

BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 7 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 7 (up to 168 weeks)
Reported as:
Mean · Z-score
Change From Baseline in BMI for Age Z-score at EOT of Cycle 7 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 7 During Teduglutide Treatment0.839 ± NA—
PrimaryChange From Baseline in BMI for Age Z-score at EOT of Cycle 8 During Teduglutide Treatment

BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 8 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 8 (up to 192 weeks)
Reported as:
Mean · Z-score
Change From Baseline in BMI for Age Z-score at EOT of Cycle 8 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 8 During Teduglutide Treatment0.015 ± NA—
PrimaryChange From Baseline in BMI for Age Z-score at EOT of Cycle 9 During Teduglutide Treatment

BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 9 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of Cycle 9 (up to 196 weeks)
Reported as:
Mean · Z-score
Change From Baseline in BMI for Age Z-score at EOT of Cycle 9 During Teduglutide Treatment
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 9 During Teduglutide Treatment0.480 ± NA—
SecondaryNumber of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Participants Diary Parenteral Support (PS) Volume at EOT of Each Cycle During Teduglutide Treatment

PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent reduction in weight-normalized diary PS values from baseline was calculated using the formula: % reduction in PS value at the visit = (\[average daily value at the scheduled visit - average daily value at baseline of the core study (SHP633-302 \[NCT02980666\]) / average daily value at baseline of the core study (SHP633-302 \[NCT02980666\])) \*100. Number of participants who achieved at least 20% reduction from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Participants Diary Parenteral Support (PS) Volume at EOT of Each Cycle During Teduglutide Treatment
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
At least 20% Reduction: At EOT of Cycle 141
At least 20% Reduction: At EOT of Cycle 241
At least 20% Reduction: At EOT of Cycle 361
At least 20% Reduction: At EOT of Cycle 451
At least 20% Reduction: At EOT of Cycle 53—
At least 20% Reduction: At EOT of Cycle 62—
At least 20% Reduction: At EOT of Cycle 71—
At least 20% Reduction: At EOT of Cycle 81—
At least 20% Reduction: At EOT of Cycle 91—
SecondaryNumber of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment

PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent reduction in weight-normalized prescribed PS values from baseline was calculated using the formula: % reduction in PS value at the visit =(\[average daily value at the scheduled visit - average daily value at baseline of the core study (SHP633-302 \[NCT02980666\]) / average daily value at baseline of the core study (SHP633-302 \[NCT02980666\])) \*100. Number of participants who achieved at least 20% reduction from baseline in Investigator prescribed PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
At least 20% Reduction: At EOT of Cycle 151
At least 20% Reduction: At EOT of Cycle 251
At least 20% Reduction: At EOT of Cycle 361
At least 20% Reduction: At EOT of Cycle 451
At least 20% Reduction: At EOT of Cycle 53—
At least 20% Reduction: At EOT of Cycle 62—
At least 20% Reduction: At EOT of Cycle 71—
At least 20% Reduction: At EOT of Cycle 81—
At least 20% Reduction: At EOT of Cycle 91—
SecondaryChange From Baseline in Participant Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment

PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Change from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Mean · mL/kg/day
Change From Baseline in Participant Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment
mL/kg/dayTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change at EOT of Cycle 1-21.5 ± 11.83-31.9 ± 16.24
Change at EOT of Cycle 2-25.5 ± 14.38-54.2 ± NA
Change at EOT of Cycle 3-32.1 ± 18.19-62.8 ± NA
Change at EOT of Cycle 4-37.2 ± 24.10-95.8 ± NA
Change at EOT of Cycle 5-54.8 ± 26.58—
Change at EOT of Cycle 6-63.8 ± 31.57—
Change at EOT of Cycle 7-93.8 ± NA—
Change at EOT of Cycle 8-80.3 ± NA—
Change at EOT of Cycle 9-79.1 ± NA—
SecondaryPercent Change From Baseline in Participant Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment

PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent change from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Mean · Percent change
Percent Change From Baseline in Participant Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent change at EOT of Cycle 1-39.6 ± 34.86-32.5 ± 18.10
Percent change at EOT of Cycle 2-44.3 ± 33.11-56.6 ± NA
Percent change at EOT of Cycle 3-52.8 ± 28.54-65.6 ± NA
Percent change at EOT of Cycle 4-62.9 ± 26.18-100.0 ± NA
Percent change at EOT of Cycle 5-73.9 ± 5.30—
Percent change at EOT of Cycle 6-75.7 ± 0.54—
Percent change at EOT of Cycle 7-82.9 ± NA—
Percent change at EOT of Cycle 8-70.9 ± NA—
Percent change at EOT of Cycle 9-69.8 ± NA—
SecondaryChange From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment

PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Change from baseline in investigator prescribed PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Mean · mL/kg/day
Change From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment
mL/kg/dayTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change at EOT of Cycle 1-20.9 ± 11.06-31.3 ± 26.77
Change at EOT of Cycle 2-28.0 ± 13.51-60.6 ± NA
Change at EOT of Cycle 3-34.8 ± 21.13-67.5 ± NA
Change at EOT of Cycle 4-36.3 ± 23.52-98.7 ± NA
Change at EOT of Cycle 5-53.3 ± 26.24—
Change at EOT of Cycle 6-63.6 ± 32.10—
Change at EOT of Cycle 7-91.8 ± NA—
Change at EOT of Cycle 8-77.3 ± NA—
Change at EOT of Cycle 9-77.9 ± NA—
SecondaryPercent Change From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment

PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent change from baseline in investigator prescribed PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Mean · Percent change
Percent Change From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent change at EOT of Cycle 1-38.8 ± 35.19-32.1 ± 26.51
Percent change at EOT of Cycle 2-46.9 ± 30.42-61.4 ± NA
Percent change at EOT of Cycle 3-55.4 ± 27.78-68.3 ± NA
Percent change at EOT of Cycle 4-62.5 ± 26.45-100.0 ± NA
Percent change at EOT of Cycle 5-73.3 ± 5.51—
Percent change at EOT of Cycle 6-76.3 ± 2.41—
Percent change at EOT of Cycle 7-83.0 ± NA—
Percent change at EOT of Cycle 8-69.9 ± NA—
Percent change at EOT of Cycle 9-70.5 ± NA—
SecondaryNumber of Participants Who Achieved Enteral Autonomy PS Volume at EOT of Each Cycle During Teduglutide Treatment

Enteral autonomy (completely weaned off PS) was defined as the first visit where there is no use of PS for the 7 days prior to the visit and there is no prescribed PS at that visit, and the participants remains off PS for the remainder of the treatment period of that cycle. Number of participants who achieved enteral autonomy off PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Enteral Autonomy PS Volume at EOT of Each Cycle During Teduglutide Treatment
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
At EOT of Cycle 110
At EOT of Cycle 210
At EOT of Cycle 310
At EOT of Cycle 411
At EOT of Cycle 50—
At EOT of Cycle 60—
At EOT of Cycle 70—
At EOT of Cycle 80—
At EOT of Cycle 90—
SecondaryChange From Baseline in Days Per Week of Diary PS Usage at EOT of Each Cycle During Teduglutide Treatment

Days per week of diary PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) \* 7. Change from baseline in days per week of diary PS usage at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Mean · Days/week
Change From Baseline in Days Per Week of Diary PS Usage at EOT of Each Cycle During Teduglutide Treatment
Days/weekTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change at EOT of Cycle 1-1.2 ± 2.860.0 ± 0.00
Change at EOT of Cycle 2-1.2 ± 2.860.0 ± NA
Change at EOT of Cycle 3-1.2 ± 2.860.0 ± NA
Change at EOT of Cycle 4-1.4 ± 3.13-7.0 ± NA
Change at EOT of Cycle 50.0 ± 0.00—
Change at EOT of Cycle 60.0 ± 0.00—
Change at EOT of Cycle 70.0 ± NA—
Change at EOT of Cycle 80.0 ± NA—
Change at EOT of Cycle 90.0 ± NA—
SecondaryChange From Baseline in Days Per Week of Prescribed PS Usage at EOT of Each Cycle During Teduglutide Treatment

Change from baseline in days per week of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported. Days per week of diary PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) \* 7. Change from baseline in days Per week of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).

Time frame:
Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Reported as:
Mean · Days/week
Change From Baseline in Days Per Week of Prescribed PS Usage at EOT of Each Cycle During Teduglutide Treatment
Days/weekTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change at EOT of Cycle 1-1.2 ± 2.860.0 ± 0.00
Change at EOT of Cycle 2-1.2 ± 2.860.0 ± NA
Change at EOT of Cycle 3-16.7 ± 40.820.0 ± NA
Change at EOT of Cycle 4-20.0 ± 44.72-100.0 ± NA
Change at EOT of Cycle 50.0 ± 0.00—
Change at EOT of Cycle 60.0 ± 0.00—
Change at EOT of Cycle 70.0 ± NA—
Change at EOT of Cycle 80.0 ± NA—
Change at EOT of Cycle 90.0 ± NA—

Adverse events

Collected over From Baseline up to follow-up (up to 50 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total Children (Aged: 1 to 15 Years)0/7 (0%)7/7 (100%)7/7 (100%)
Infants (Corrected Gestational Age: 4 to < 12 Months)0/2 (0%)2/2 (100%)2/2 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Device related infectionInfections and infestations4/71/2
Pancreatitis acuteGastrointestinal disorders0/71/2
Gastroenteritis adenovirusInfections and infestations0/71/2
Otitis mediaInfections and infestations0/71/2
Upper respiratory tract infectionInfections and infestations0/71/2
Viral upper respiratory tract infectionInfections and infestations0/71/2
SeizureNervous system disorders0/71/2
Device breakageProduct Issues3/71/2
Device damageProduct Issues2/70/2
Colonic haematomaGastrointestinal disorders1/70/2
Most frequent other events
Showing 10 of 81
Most frequent other events
EventTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Viral upper respiratory tract infectionInfections and infestations4/71/2
Injection site reactionGeneral disorders0/71/2
ConjunctivitisInfections and infestations1/71/2
Medical device site infectionInfections and infestations1/71/2
Oral candidiasisInfections and infestations0/71/2
Upper respiratory tract infectionInfections and infestations0/71/2
Viral infectionInfections and infestations0/71/2
Auricular haematomaInjury, poisoning and procedural complications0/71/2
ContusionInjury, poisoning and procedural complications0/71/2
Alanine aminotransferase increasedInvestigations0/71/2

Baseline characteristics

The safety population included all enrolled participants in the study and who received at least one dose of teduglutide (in study SHP633-302 \[NCT02980666\] or SHP633-305 \[NCT03268811\]).

Age, Customized
Age, Customized(Participants)Total Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)Total
Aged: 1 to 15 Years707
Aged: 4 to < 12 Months022
Sex: Female, Male
Sex: Female, Male(Participants)Total Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)Total
Female112
Male617
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Total Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)Total
Hispanic or Latino000
Not Hispanic or Latino729
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Total Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)Total
American Indian or Alaska Native000
Asian729
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

6 sites
  • Akita University Hospital
    Akita-shi, Akita-ken 010-8543, Japan
  • Kyushu University Hospital
    Fukuoka-shi, Fukuoka-ken 812-8582, Japan
  • Tsukuba University Hospital
    Tsukuba, Ibaraki-Ken 305-8576, Japan
  • Kagoshima University Hospital
    Kagoshima, Kagoshima-Ken 890-8520, Japan
  • Tohoku University Hospital
    Sendai-shi, Miyagi-Ken 980-8574, Japan
  • Showa University Hospital
    Shinagawa-ku, Tokyo-To 142-8666, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, ...).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Nov 2021, 50 months.

Results were first posted in May 2022, 6 months after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 50 months is above that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2017
First posted
Aug 31, 2017
StartActual
Aug 23, 2017
Primary completionActual
Nov 2, 2021
CompletionActual
Nov 2, 2021
Results first posted
May 24, 2022
Last update
May 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03268811
Lead sponsor
Shire
Collaborators
Takeda
Responsible party
Sponsor
First posted
Aug 31, 2017
Start date
Aug 23, 2017
Primary completion
Nov 2, 2021
Completion
Nov 2, 2021
Results posted
May 24, 2022
Last update
May 24, 2022

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion